els, as well as the surface levels of Na v channel α-subunits, were also significantly reduced in PS1(E280A) cells. Conclusion: Our data indicate that the FAD-linked PS1(E280A) mutation decreases Na v channel levels by partially inhibiting the PS/γ-secretase-mediated cleavage of Na v β 2 in neuronal cells.
Introduction
Mutations in the presenilin 1 (PS1) gene (PSEN1) is the most common genetic cause of familial Alzheimer's disease (FAD) [1] . PS1 mutations are likely to exert their pathophysiological effect by altering the PS1/γ-secretase-mediated cleavage of the amyloid-β (Aβ) precursor protein, resulting in increased Aβ 42/40 ratios [2, 3] . PSEN1 FAD patients are affected by early-onset cognitive decline typical of AD, but additional symptoms are also present in patients with select FAD mutations [4] . These include myoclonus and/or seizures, apraxia, dystonia, and behavioral and psychiatric symptoms [4] [5] [6] . However, molecular mechanisms underlying these atypical symptoms are not fully understood.
Previously, we and others reported that the β 2 -subunit of the voltage-gated sodium channel (Na v β 2 ) is a substrate of BACE1 and PS/γ-secretase [7] [8] [9] [10] . We found that PS/ γ-secretase-mediated cleavages of Na v β 2 C-terminal fragments (β 2 -CTFs) released the intracellular domains of Na v β 2 (β 2 -ICDs), which were localized to the nucleus, and increased mRNA and protein levels of the Na v channel α-subunit, Na v 1.1 [7] [8] [9] 11] . These studies clearly demonstrate that PS/γ-secretase-mediated processing of Na v β 2 plays a major role in regulating neuronal sodium channel Na v 1.1. Since Na v 1 channels play an important role in neural activity, we tested if specific PS1 FAD mutations contribute to abnormal Na v 1.1 levels by altering Na v β 2 processing.
Methods

Constructs, Transfection and Cell Lines
The construct encoding full-length human Na v β 2 containing a C-terminal V5/His tag was described previously [8] . Constructs containing human wild-type PS1 (wtPS1) and PS1(ΔE9) and PS1(D333G) were a kind gift from Dr. John Hardy (National Institutes of Health). For PS1(E280A) and PS1(M146L) constructs, mutations were introduced into wtPS1 by site-directed mutagenesis (Promega). Effectene (Qiagen) was used for transfection, and individual clones were maintained in selection medium containing Zeocin (Invitrogen) and G418 (CellGro).
Western Blot Analysis, Antibodies and Inhibitors
Cell extraction and Western blot analyses were performed as previously described [7] . Primary antibodies were used at the following dilutions: anti-V5 (1: 5,000; Invitrogen), anti-Na v 1.1 (1: 250; Millipore), anti-pan Na v 1 α-subunit (1: 250; Millipore), anti-PS1 (1: 250; Millipore), anti-glyceraldehyde-3-phosphate dehydrogenase (1: 250; Millipore), anti-N-cadherin (1: 1,000; BD Transduction Laboratory), and anti-transferrin receptor (1: 1,000; Sigma). The γ-secretase inhibitors DAPT and L-685,458 were obtained from Calbiochem. Blots were quantified using the Versa Doc imaging system and Quantity One software (Bio-Rad).
Cell-Free γ-Secretase Cleavage Assay
In vitro γ-secretase assay was performed as previously described [8] . Purified membrane fractions were resuspended in a reaction buffer and incubated at 0 or 37 ° C for 2 h in the presence or absence of L-685,458.
RNA Extraction, cDNA Synthesis and Quantitative Real-Time RT-PCR
Relative Na v 1.1 mRNA levels were measured by quantitative real-time RT-PCR as previously described [7] . All experiments were normalized to glyceraldehyde-3-phosphate dehydrogenase controls.
Cell Surface Biotinylation
Cell surface biotinylation and detection of surface Na v 1 α-subunits were performed as previously described [7, 12] .
Results and Discussion
To study the effects of PS1 mutations on Na v 1 channels, we stably cotransfected B104 rat neuroblastoma cells with Na v β 2 and wtPS1 or PS1(E280A) or PS1(M146L), both FAD mutations which are associated with clinical seizures, or with PS1(ΔE9), a FAD mutation with no reported seizures, or with PS2(D333G), a non-FAD-linked mutation [4, 5] . B104 cells express endogenous Na v 1 channel components and have previously been used for studying Na v 1.1 channel regulation by BACE1 and PS/γ-secretase [7] . In these cells, we first analyzed levels of β 2 -CTF, a direct substrate for PS/γ-secretase (online suppl. fig. 1a ; for all online suppl. material, see www.karger.com/doi/10.1159/000354669). Interestingly, we found that a seizure-related FAD-linked PS1 mutation, E280A, increased β 2 -CTF levels by 3.7 fold as compared to the control cells ( fig. 1 a; online suppl. fig. 1b ). We also observed a moderate increase in β 2 -CTF levels (1.9 fold) in PS1(M146L) cells but this did not reach statistical significance ( fig. 1 a; online suppl. fig. 1b ). Ectodomain shedding by ADAM10 or BACE1 was not increased, since we were unable to detect elevated β 2 -CTF levels in the same cells pretreated with the PS/γ-secretase inhibitor DAPT ( fig. 1 a) . This indicates that the E280A mutation prevents PS/γ-secretase cleavage of Na v β 2 .
To confirm this, we quantitated levels of the PS/γ-secretase cleavage product β 2 -ICD ( fig. 1 b, c) . Since β 2 -ICDs are quickly degraded within the cytoplasm, a cellfree γ-secretase cleavage assay system ( fig. 1 b) or overexpression of recombinant myc-tagged β 2 -CTF substrates ( fig. 1 c) are required to detect β 2 -ICDs. Both assays showed a dramatic decrease in β 2 -ICDs with PS1(E280A) expression ( fig. 1 b, c) . Steady-state levels of myc-β 2 -CTF were largely elevated in PS1(E280A) cells as compared to wtPS1 controls (online suppl. fig. 2b, c) . Together, these data demonstrate that the PS1(E280A) mutation decreases PS/γ-secretase-mediated Na v β 2 cleavages in neuronal cells.
Next, we tested whether the PS1(E280A) mutation reduces Na v 1.1 levels by decreasing β 2 -ICD levels. By using quantitative real-time RT-PCR, we analyzed Na v 1.1 mRNA levels of PS1(E280A) and wtPS1 cell clones [(n = 4 for PS1(E280A) and n = 3 for wtPS1)]. We found that Na v 1.1 mRNA levels are dramatically decreased in PS1(E280A) cells as compared to wtPS1 cells, which is consistent with decreased β 2 -ICD levels in these cells ( fig. 2 a) . As expected, we also found that Na v 1.1 protein levels were significantly decreased in PS1(E280A) cells ( fig. 2 b) . These data strongly indicate that the PS1(E280A) mutation decreased Na v 1.1 levels by reducing β 2 -ICD generation in these cells.
To test whether the decrease in Na v 1.1 levels led to a reduction in functional Na v 1 channels, we analyzed cell surface levels of Na v 1 α-subunits ( fig. 2 c, d) . We have previously shown that decreases in surface Na v 1 α-subunit levels were directly responsible for decreased sodium currents in the same cells [7] . By using a cell surface biotinylation assay, we found that surface Na v 1 α-subunit levels were dramatically decreased in PS1(E280A) cells as compared to wtPS1 controls ( fig. 2 c, d ). Pharmacological inhibition of PS/γ-secretase activity confirmed our data with PS1(E280A) overexpression, as DAPT robustly reduced surface Na v 1 α-subunit levels in B104 cells expressing Na v β 2 without PS1(E280A) expression (online suppl. fig. 3 ). Together, our results indicate that the PS1(E280A) mutation decreased PS/γ-secretase-mediated cleavage of Na v β 2 , β 2 -ICD generation, Na v 1.1 α-subunit precursor levels, and therefore, reduced the surface Na v 1 channels and possibly the sodium currents and membrane excitability ( fig. 3 ) .
Recently, we reported that BACE1 ablation decreased Na v 1.1 mRNA and protein levels in mouse brains due to reduced endogenous β 2 -ICD levels [9] . Consistent with our findings, Hu et al. [13] showed that Na v 1.1 and Na v 1.2/6 levels were significantly decreased in BACE1-null mice, although the changes in Na v 1.2/6 were not observed in other reports [13, 14] . A recent study in the PS/ Aβ precursor protein AD mouse model also showed that elevated BACE1 levels in these mice led to the accumulation of endogenous β 2 -ICD in the nuclei of cortical neurons, increased Na v 1.1 levels and possibly contributed to aberrant neuronal activity and cognitive deficits [15] . Together, these data strongly support a physiological role of β 2 -ICD in regulating Na v 1.1 levels in brains.
AD patients with PS1(E280A) mutation display frequent epileptic seizures at early ages, and a study showed that the early-onset seizures in PS1(E280A) patients strongly associated with CA1 hippocampal neuronal loss [5, 16, 17] . Recent studies in AD mouse models also provide strong evidence that altered Na v 1.1 channel levels are responsible for seizures, abnormal neural activities and even a cognitive decline in these mice [15, 18] . Therefore, 68 our findings suggest a novel molecular pathway that can contribute to AD pathology in patients with PS1(E280A) mutation. Further studies will be required to fully elucidate whether PS1(E280A) and possibly other epilepsy-associated PS FAD mutations contribute to AD pathology by modulating Na v 1.1 channels in vivo.
